Udskriv Udskriv
Switch language
Hvidovre Hospital - en del af Københavns Universitetshospital

A Danish population-based case series of patients with liver cirrhosis and coronavirus disease 2019

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

Vis graf over relationer

Objectives: Coronavirus disease 2019 (COVID-19) is an ongoing major health emergency, but its occurrence and clinical impact on patients withliver cirrhosis is unknown. Therefore, we conducted a population-based study of 2.6 million Danish citizens investigating the occurrence and impact of COVID-19 in patients with liver cirrhosis. Materials and methods: A prospective population-based cohort study was conducted in the Capital Region of Denmark and Region Zealand in the study period between 1 March 2020 up until 31 May 2020, with the only eligibility criteria being a reverse-transcriptase polymerase chain reaction for presence of viral genomic material confirming COVID-19. The patients were subsequently stratified according to presence of pre-existing liver cirrhosis. Results: Among 575,935 individuals tested, 1713 patients had a diagnosis of cirrhosis. COVID-19 occurredsignificantly lessamongpatients with cirrhosis (n = 15; 0.9%, p <.01) compared with the population without cirrhosis (n = 10,593; 1.8%). However, a large proportion (n = 6;40.0%) required a COVID-19 related hospitalization which was correlated with higher values of alanine aminotransferase (p <.01) and lactate dehydrogenase (p =.04). In addition, one-in-three (n = 2; 13.3%) required intensive therapy. Four patients died (26.7%) and mortality was associated with higher MELD scores, co-existing type 2 diabetes, and bacterial superinfections. Conclusion: In conclusion, patientswith cirrhosis may have a lower risk of COVID-19; but a higher risk of complications hereto and mortality.

TidsskriftScandinavian Journal of Gastroenterology
Udgave nummer4
Sider (fra-til)453-457
Antal sider5
StatusUdgivet - apr. 2021

Bibliografisk note

Funding Information:
JB: personal fees from AbbVie, Janssen-Cilag, Celgene, Samsung Bioepis, and Pfizer; grants and personal fees from Takeda, MSD and Tillots Pharma; Grants from Novo Nordisk Foundation, and Bristol Meyers Squibb. None of these pertain to the research submitted here.

Funding Information:
NK: Nina Kimer is employed through a grant from Novo Nordisk Foundation (NNF18SA0034956).

ID: 62309832